• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by European Biotech Acquisition Corp.

    2/8/22 4:10:06 PM ET
    $EBAC
    Blank Checks
    Finance
    Get the next $EBAC alert in real time by email
    SC 13G 1 dp166832_sc13g-ebac.htm FORM SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G
    (Amendment No.)*

     

    Under the Securities Exchange Act of 1934

     

    European Biotech Acquisition Corp.

    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)

     

    G3167F 110
    (CUSIP Number)

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. G3167F 110 Schedule 13G  
    1

    NAME OF REPORTING PERSON

     
    LSP Sponsor EBAC B.V.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Netherlands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    - 0 -

    6

    SHARED VOTING POWER

     

    3,593,792 (1)

    7

    SOLE DISPOSITIVE POWER

     

    - 0 -

    8

    SHARED DISPOSITIVE POWER

     

    3,593,792 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,593,792 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    21.92% (1)

    12

    TYPE OF REPORTING PERSON

     

    OO

               

     

     

    CUSIP No. G3167F 110 Schedule 13G  
    1

    NAME OF REPORTING PERSON

     
    LSP Management Group B.V.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Netherlands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    - 0 -

    6

    SHARED VOTING POWER

     

    3,593,792 (1)

    7

    SOLE DISPOSITIVE POWER

     

    - 0 -

    8

    SHARED DISPOSITIVE POWER

     

    3,593,792 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,593,792 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    21.92% (1)

    12

    TYPE OF REPORTING PERSON

     

    CO

               

     

     

    CUSIP No. G3167F 110 Schedule 13G  
    1

    NAME OF REPORTING PERSON

     
    Martijn Kleijwegt

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Netherlands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    - 0 -

    6

    SHARED VOTING POWER

     

    3,593,792 (1)

    7

    SOLE DISPOSITIVE POWER

     

    - 0 -

    8

    SHARED DISPOSITIVE POWER

     

    3,593,792 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,593,792 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    21.92% (1)

    12

    TYPE OF REPORTING PERSON

     

    IN

               

     

     

    CUSIP No. G3167F 110 Schedule 13G  
    1

    NAME OF REPORTING PERSON

     
    Mark Wegter

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Netherlands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    - 0 -

    6

    SHARED VOTING POWER

     

    3,593,792 (1)

    7

    SOLE DISPOSITIVE POWER

     

    - 0 -

    8

    SHARED DISPOSITIVE POWER

     

    3,593,792 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,593,792 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    21.92% (1)

    12

    TYPE OF REPORTING PERSON

     

    IN

               

    (1) See Item 4 below. The Reporting Person owns (i) 3,138,696 Class B Ordinary Shares of the Issuer, which are automatically convertible into the Issuer’s Class A Ordinary Shares as more fully described under the heading “Description of Securities—Founder Shares” in the Issuer’s registration statement on Form S-1 (File No. 333-253220) and (ii) 455,096 shares underlying the private placement units.

     

     

     

    Item 1(a). Name of Issuer:

     

    European Biotech Acquisition Corp. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands

     

    Item 2(a). Name of Person Filing:

     

    LSP Sponsor EBAC B.V. (the “Reporting Person”)

     

    LSP Management Group B.V.

     

    Martijn Kleijwegt

     

    Mark Wegter

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    LSP Sponsor EBAC B.V. – Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands

     

    LSP Management Group B.V. – Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands

     

    Martijn Kleijwegt – Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands

     

    Mark Wegter – Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands

     

    Item 2(c). Citizenship:

     

    LSP Sponsor EBAC B.V. – Netherlands

     

    LSP Management Group B.V. – Netherlands

     

    Martijn Kleijwegt – Netherlands

     

    Mark Wegter – Netherlands

     

    Item 2(d). Titles of Classes of Securities:

     

    Class A Ordinary Shares, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number:

     

    G3167F 110

     

     

     

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

    (a) ☐   Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
    (b) ☐   Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c)
    (c) ☐   Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
    (d) ☐   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ☐   Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
    (f) ☐   Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g) ☐   Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h) ☐   Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) ☐   Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j) ☐   Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).
    (k) ☐   Group in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference.

     

    As of December 31, 2021, the Reporting Person may be deemed to beneficially own 3,138,696 shares of the Issuer’s Class B Ordinary Shares and 455,096 of the Issuer’s Class A common stock, representing 21.92% of the total Class A and Class B Ordinary Shares issued and outstanding. The Class B Ordinary Shares are automatically convertible into the Issuer’s Class A Ordinary Shares at the time of the Issuer’s initial business combination on a one-for-one basis, subject to adjustment, as more fully described under the heading “Description of Securities—Founder Shares” in the Issuer’s registration statement on Form S-1 (File No. 333-253220).

     

    LSP Management Group B.V., a Dutch limited liability company, is the majority owner of the Reporting Person and as such, LSP Management Group B.V. has voting and investment discretion with respect to the shares held of record by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Martijn Kleijwegt and Mark Wegter who are directors of LSP Management Group B.V. have voting and investment discretion with respect to the shares owned by LSP Management Group B.V. and may be deemed to have indirect shared beneficial ownership of the shares held by the Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certification.

     

    Not Applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2022

     

      European Biotech Acquisition Corp.
       
       
     

    /s/ Eduardo Bravo

      Name: Eduardo Bravo
      Title:    CEO
       
       
     

    LSP Sponsor EBAC B.V.

       
       
     

    /s/ Martijn Kleijwegt

      Name: Martijn Kleijwegt
      Title:    Director
       
     

    /s/ Mark Wegter

      Name: Mark Wegter
      Title:    Director
     

     

     

      LSP Management Group B.V.
       
     

    /s/ Martijn Kleijwegt

      Name: Martijn Kleijwegt
      Title:    Director
       
     

    /s/ Mark Wegter

      Name: Mark Wegter
      Title: Director
     

     

    Martijn Kleijwegt

       
       
     

    /s/ Martijn Kleijwegt

       
       
     

    Mark Wegter

       
       
     

    /s/ Mark Wegter

     

     

     

     

    Exhibit Index

     

    Exhibit Description
    Exhibit A

    Joint Filing Agreement dated, February 8, 2022, by and among LSP Sponsor EBAC B.V., LSP Management Group B.V., Martijn Kleijwegt and Mark Wegter.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned hereby agrees that they are filing jointly pursuant to Rule 13-d-1(k)(1) of the Securities Exchange Act of 1934, as amended, with respect to ordinary shares of Class A Ordinary Shares of European Biotech Acquisition Corp. The undersigned further agree and acknowledge that such shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein, but shall not be responsible for completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 8, 2022

     

      European Biotech Acquisition Corp.
       
       
     

    /s/ Eduardo Bravo

      Name: Eduardo Bravo
      Title:    CEO
       
       
     

    LSP Sponsor EBAC B.V.

       
       
     

    /s/ Martijn Kleijwegt

      Name: Martijn Kleijwegt
      Title:    Director
       
     

    /s/ Mark Wegter

      Name: Mark Wegter
      Title:    Director
     

     

     

      LSP Management Group B.V.
       
       
     

    /s/ Martijn Kleijwegt

      Name: Martijn Kleijwegt
      Title:    Director
       
     

    /s/ Mark Wegter

      Name: Mark Wegter
      Title: Director
       
     

     

    Martijn Kleijwegt

       
       
     

    /s/ Martijn Kleijwegt

       
       
     

    Mark Wegter

       
       
     

    /s/ Mark Wegter

     

      

     

     

    Get the next $EBAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EBAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

      Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populationsNet proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the fir

      10/17/22 9:03:45 AM ET
      $EBAC
      Blank Checks
      Finance

    $EBAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by European Biotech Acquisition Corp.

      SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)

      2/14/23 11:32:47 AM ET
      $EBAC
      Blank Checks
      Finance
    • SEC Form SC 13G filed by European Biotech Acquisition Corp.

      SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)

      2/13/23 4:04:05 PM ET
      $EBAC
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)

      SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)

      2/6/23 4:43:20 PM ET
      $EBAC
      Blank Checks
      Finance

    $EBAC
    SEC Filings

    See more
    • SEC Form 15-12G filed by European Biotech Acquisition Corp.

      15-12G - European Biotech Acquisition Corp. (0001841258) (Filer)

      3/13/23 4:09:32 PM ET
      $EBAC
      Blank Checks
      Finance
    • SEC Form 25-NSE/A filed by European Biotech Acquisition Corp. (Amendment)

      25-NSE/A - European Biotech Acquisition Corp. (0001841258) (Subject)

      3/2/23 4:29:30 PM ET
      $EBAC
      Blank Checks
      Finance
    • European Biotech Acquisition Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - European Biotech Acquisition Corp. (0001841258) (Filer)

      2/28/23 4:11:13 PM ET
      $EBAC
      Blank Checks
      Finance